Genenta Science’s (GNTA) Buy Rating Reiterated at HC Wainwright

HC Wainwright reissued their buy rating on shares of Genenta Science (NASDAQ:GNTA) in a research note published on Wednesday, Benzinga reports. They currently have a $25.00 price objective on the stock.

Genenta Science Price Performance

Genenta Science stock opened at $4.40 on Wednesday. Genenta Science has a one year low of $2.20 and a one year high of $5.87. The business has a fifty day moving average price of $4.14 and a 200-day moving average price of $3.67.

Institutional Investors Weigh In On Genenta Science

A hedge fund recently bought a new stake in Genenta Science stock. AlTi Global Inc. bought a new position in shares of Genenta Science S.p.A. (NASDAQ:GNTA) during the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor bought 200,288 shares of the company’s stock, valued at approximately $621,000. AlTi Global Inc. owned 1.10% of Genenta Science at the end of the most recent quarter. Hedge funds and other institutional investors own 15.13% of the company’s stock.

Genenta Science Company Profile

Genenta Science S.p.A., a clinical-stage biotechnology company, engages in the development of hematopoietic stem cell gene therapies for the treatment of solid tumors in Italy. Its lead product candidate is Temferon, which is in Phase 1/2a clinical trials for use in the treatment of glioblastoma multiforme in patients with unmethylated MGMT gene promoter.